Title:  Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes

United States Patent:  6,207,170

Assignee:  Biomira U.S.A., Inc. (Cranbury, NJ)

Filed:  January 15, 1999

Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific.

DETAILED DESCRIPTION OF THE INVENTION

Introduction

The instant invention provides membrane-proteoliposome structures (MPs) that are useful in formulating patient-specific vaccines for treating white blood cell (WBC) malignancies.

The inventors previously described a proteoliposomal vaccine made of antigen idiotype (Id) and interleukin-2 (IL-2) proteins within a liposomal structure (Popescu, et al., PCT/US97/02351). In contrast to that earlier work, a novel liposomal structure is disclosed herein, called a membrane-proteoliposome (MP), which usually comprises phospholipid, integral membrane from a malignant WBC and a potent immunostimulator. The present invention is based in part on the discovery that membranes from WBC malignancies can be fused with other components to form an effective vaccine against the malignancy.

All WBCs, including polymorphonuclear cells (PMN), monocytes and T- or B-lymphocytes, are subject to malignant transformation leading to a spectrum of diseases. For example, B-cell malignancy includes non-Hodgkin's lymphomas, chronic lymphocytic leukemia and multiple myeloma. The present invention has relevance in treating or preventing many such malignancies.

In preparing the inventive vaccines, WBC's can be obtained directly from the patient to isolate the intact membranes, rich in tumor-specific antigens (TSA) and tumor-associated antigens (TAA). In general cells will be enucleated and their plasma membranes separated from other components (e.g., mitochondria, lysosomes). The plasma membranes typically are washed to remove cellular contaminates, which may include cytoskeletal structures, and the separation material. The plasma membrane suspensions may then be exposed to mechanical size reduction, for example, by extrusion, homogenization or other shearing methods. This will allow for filtration through a sterilizing filter. The WBC membranes may also be detergent solubilized, reconstituted with lipids of choice then size reduced. In lieu of mechanical size reduction methods, the isolated membranes may be sterilized by, for example, .gamma.-irradiation.

The isolated malignant cell membranes, alone or in combination with added lipids, can then be used to entrap an immunomodulator. The extent of entrapment of immunomodulator, immunogenicity and efficacy of the MP as a vaccine can be modulated by the nature of the constitutive lipids. A thus optimized MP formulation may then be used to vaccinate the patient against his/her specific WBC malignancy.

The present invention is particularly useful in vaccinating against non-Hodgkin's lymphomas. These lymphomas are characterized by the expression of monotypic immunoglobulin (Ig) which can serve as a tumor-specific antigen. In addition, these cells typically express surface molecules involved in antigen presentation, such as class I and class II MHC molecules (with associated TSA or TAA peptide), and costimulation, such as adhesion proteins and B7.1 and B7.2 (CD80 and CD86). In particular, the presence of a class I MHC molecule in the inventive formulation will potentially enhance the cytotoxic immune response against the tumor. These characteristics make the B-cell lymphoma plasma membrane an attractive candidate that can be used as a potentially strong immunogenic tool in active specific immunotherapy.

The present invention provides a proteoliposomal, patient-specific vaccine for WBC malignancies that, in one embodiment, is produced by entrapping a potent immunomodulator together with malignant white blood cell membranes. The resulting membrane-proteoliposome can be either (1) a cell-derived membrane patched with at least one added membrane-forming lipid or (2) a lipid membrane (e.g., a liposome) patched with cell-derived membrane. By "patched" is meant that the resulting MP is non-homogenous with respect to the component lipid sources. Thus, contiguous portions of the MP will be essentially WBC membrane-derived, while others will be derived essentially from the added membrane-forming lipids. In three examples below, MP formulations are described which contain membrane from a mouse B-cell lymphoma (38C13), and which were used as effective vaccines in a mouse model of non-Hodgkin's B-cell lymphoma.

Vaccine Compositions of the Invention

The vaccine compositions of the invention typically comprise at least one membrane component of a malignant white blood cell. Important membrane components specifically include components involved in immunity. Components involved in immunity can include any macromolecules, such as proteins, lipids and carbohydrates, which are normally an integral part of, or simply associated with, the cell membrane. Other organic and inorganic substances which are similarly associated with the cell membrane also are included. Some preferred components involved in immunity include tumor-specific antigens (TSA), tunor associated antigens (TAA), major histocompatability (MHC) antigens (class I and class II molecules) and costimulatory molecules.

Costimulatory molecules are second signal immunostimulators associated with T cell activation. Costimulatory molecules typically are cell surface molecules which act in conjunction with primary immune signals, i.e., antigen presented by MHC molecules, to generate an immune response. Thus, acting in concert, primary and secondary signal molecules facilitate antigen presentation by antigen presenting cells (APC) to T cells. Examples of costimulatory molecules include cellular adhesion molecules and CD-40. Specific preferred costimulatory molecules include B7.1, B7.2 and ICAM-1 (CD 56).

Preferably, the membrane component takes the form of an isolated plasma membrane (in whole or in part). The isolated plasma membrane preferably is constituted of lipid which is membrane-forming. Thus, all components normally integral to or associated, with the cell plasma membrane, including components involved in immunity, typically are present. This preferred membrane component will usually be isolated from a patient sought to be vaccinated. Thus, the resultant vaccine comprising this membrane component will be patient-specific and specific for the WBC malignancy from which the membrane component is isolated. It is envisioned that a vaccine formulated with a membrane component from one patient will be useful in vaccinating another patient, given similar antigenic determinants. Of course, it is also possible, due to cross-reactivity or common antigenic determinants, that the vaccine for one malignancy will prove useful in vaccinating against another malignancy. Thus, as used herein, "patient-specific" refers to the fact that the vaccine is derived from a particular patient (it thus will be useful in treating that same patient), not that it is useful only to treat the patient or the specific malignancy from which it is derived. Although the patient will normally be human, non-human animals may also be patients.

The inventive vaccine compositions can be made specific for any white blood cell malignancy. The clinician will be familiar with the various types of white blood cells and their malignancies. Representative white blood cells include polymorphonuclear cells (PMNs), monocytes, T-lymphocytes and B-lymphocytes. Some representative white blood cell malignancies include lymphomas, leukemias, and myelomas. Other white blood cell malignancies are known in the art. Further examples of WBC malignancies are found in McCance et al., PATHOPHYSIOLOGY: THE BIOLOGIC BASIS OF DISEASE IN ADULTS AND CHILDREN, chapters 24 and 25, pp. 800-855 (The C.V. Mosby Company 1990), which are hereby incorporated by reference.

Some preferred vaccine compositions further comprise at least one immunostimulator. Immunostimulators specifically include any substance that can be used to modulate the immune response. Especially useful immunostimulators are those which can be used to stimulate the specific immune response to components involved in immunity. Exemplary classes of such useful immunostimulators include: lymphokines, such as IL-2, IL-4 and IL-6; interferons, such as IFN-.gamma. and IFN-.alpha.; other cytokines, such as GM-CSF and M-CSF; and adjuvants, such as Lipid A, monophosphoryl lipid A (MPL), or muramyl dipeptide (MDP). Immunostimulators may be used alone or in any combination with one another. Some compositions comprise at least two immunostimulators, such as IL-2 and MPL or MDP, and other combinations of cytokines with adjuvants.

Other preferred vaccine compositions comprise lipids other than those present in the cell membrane component (i.e., from an exogenous source). These "exogenous" lipids may be from natural or synthetic sources. Preferred lipids include phospholipids, glycolipids, and especially saturated phospholipids. Saturated phospholipids include 1,2-dimyristoylphosphatidylcholine (DMPC), 1,2-dipalmitoylphosphatidylcholine (DPPC), 1,2-dimyristoylphosphatidylglycerol (DMPG). Other useful lipids include cholesterol and derivatives thereof. Of course combinations of these and other lipids are also useful.

Methods for Preparing the Inventive Vaccines

Preparing an inventive vaccine involves first isolating WBC membrane components, free of other cellular components. One such example is provided below as Example 4. According to a preferred embodiment, isolated membranes typically are combined with other lipids and/or immunostimulators to form MPs. There are many liposome-forming methods known in the art and any of these standard methods may be employed in preparing the present MP.

In one exemplary method MPs can be prepared containing IL-2 as an immunostimulator. The IL-2 is mixed with the WBC membranes and entrapped by freeze/thawing from -70^oC. to 37^oC., followed by brief vortexing and short bath sonication (30 seconds). The preparation can include the addition of a suitable lipid powder at 50 to 300 mg/nL (final). Thus, using this method MPs can be formed independent of exogenous lipids or from WBC membrane components mixed with exogenous lipids.

MPs can also be prepared containing only WBC membrane components, which may be fused with preexisting liposomes which comprise exogenous lipids. A WBC membrane suspension is lyophilized then hydrated with a suitable liquid, for example, water, normal saline solution (NSS) or a suitable buffer. The hydration liquid may contain an inununomodulator. Thus, MPs comprising WBC membrane components are formed. In addition, pre-formed multilamellar vesicles (MLVs), composed of suitable exogenous liposome-competent lipids, may be mixed with the WBC membrane suspension prior to lyophilization. The MLVs may contain a pre-incorporated immunomodulator, in which case the lyophilized preparation is hydrated with a suitable liquid, which may contain at least one immunomodulator. Thus, in any method for preparing MPs, any combination of multiple immunostimulators may be incorporated at any suitable point in the process.

In another method, the WBC membrane suspension is size reduced by extrusion, homogenization or other shearing methods to form small unilamellar vesicles (SUVs). The SUVs are then lyophilized and hydrated with a suitable liquid, optionally containing an immunomodulator. SUVs prepared from exogenous lipids also may be added prior to the lyophilization step. In addition, the immunomodulator may be mixed with the SUV's prior to lyophilization. In any event, whenever the lyophilized preparation is hydrated, the liquid may contain an immunomodulator.

In yet another method, a WBC membrane suspension is added to MLVs comprising exogenous lipids. The resulting mixture is lyophilized and hydrated with water, NSS or buffer followed by size reduction (extrusion, homogenization or other shearing methods) to form SUV's. An immunomodulator may be added and the mixture is allowed to fuse overnight.

Another method involves adding a WBC membrane suspension to MLVs comprising exogenous lipids. The mixture is lyophilized and hydrated with a suitable liquid. The resulting suspension is size reduced by extrusion, homogenization or other shearing methods to form SUVs. The SUVs are lyophilized and hydrated with a suitable liquid, optionally containing an immunomodulator.

Also, the WBC membrane suspension may be size reduced by extrusion, homogenization or other shearing methods to form SUVs. An immunomodulator is added to the SUVs and the mixture is then allowed to fuse overnight.

Vaccines may also be formulated with a pharmaceutically acceptable excipient. Such excipients are well known in the art, but typically should be physiologically tolerable and inert or enhancing with respect to the vaccine properties of the inventive compositions. When using an excipient, it may be added at any point in formulating the vaccine or it may be admixed with the completed vaccine composition.

Vaccines may be formulated for multiple routes of administration. Specifically preferred routes include intramuscular, percutaneous, subcutaneous, or intradermal injection, aerosol, oral or by a combination of these routes, at one time, or in a plurality of unit dosages. Administration of vaccines is well known and ultimately will depend upon the particular formulation and the judgement of the attending physician.

Vaccine formulations can be maintained as a suspension, or they may be lyophilized and hydrated later to generate a useable vaccine.

Claim 1 of 21 Claims

What is claimed is:

1. A patient-specific vaccine for treating white blood cell malignancy, comprising a membrane-proteoliposome (MP) containing plasma membrane from a malignant white blood cell.

____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.